National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 14277-14278 [2022-05286]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 49 / Monday, March 14, 2022 / Notices
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; MultiComponent Application.
Date: March 31, 2022.
Time: 9:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Dario Dieguez, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institutes of Health,
National Institute on Aging, Bethesda, MD
20814, (301) 827–3101, dario.dieguez@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Date: April 8, 2022.
Time: 1:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health, 6701
Rockledge Dr., Bethesda, MD 20817 (Virtual
Meeting).
Contact Person: Robert C Elliott, Ph.D., AB,
MS, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5190,
MSC 7846, Bethesda, MD 20892, 301–435–
3009, elliotro@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–RM–
21–015: 2022 Pioneer Award Review.
Date: April 12–14, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: James W Mack, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4154,
MSC 7806, Bethesda, MD 20892, (301) 435–
2037, mackj2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 8, 2022.
David W Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: March 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–05282 Filed 3–11–22; 8:45 am]
[FR Doc. 2022–05283 Filed 3–11–22; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
jspears on DSK121TN23PROD with NOTICES1
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Vision Pathology and Dysfunction.
VerDate Sep<11>2014
17:51 Mar 11, 2022
Jkt 256001
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, NIDA. The meeting will be
closed to the public as indicated below
in accordance with the provisions set
forth in sections 552b(c)(6), Title 5
U.S.C., as amended for the review,
discussion, and evaluation of individual
intramural programs and projects
conducted by the National Institute on
Drug Abuse, including consideration of
personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Board of Scientific
Counselors, NIDA.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
14277
Date: May 3, 2022.
Time: 8:30 a.m. to 5:45 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: National Institute on Drug Abuse,
NIH, Biomedical Research Center, 251
Bayview Boulevard, Baltimore, MD 21224
(Virtual Meeting).
Contact Person: Deon M. Harvey, Ph.D.,
Management Analyst, Office of the Scientific
Director, National Institute on Drug Abuse,
251 Bayview Boulevard, Room 04A314,
Baltimore, MD 21224, (443) 740–2466
deon.harvey@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: March 8, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–05285 Filed 3–11–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Innate Immune Memory
Impacting HIV Acquisition and/or Control
(R21 Clinical Trial Not Allowed).
Date: April 11–12, 2022.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E71,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Lee G. Klinkenberg, Ph.D.,
Scientific Review Officer, Scientific Review
E:\FR\FM\14MRN1.SGM
14MRN1
14278
Federal Register / Vol. 87, No. 49 / Monday, March 14, 2022 / Notices
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3E71, Rockville, MD
20852, 301–761–7749, lee.klinkenberg@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: March 8, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–05286 Filed 3–11–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
[1651–0019]
Vessel Entrance or Clearance
Statement
U.S. Customs and Border
Protection (CBP), Department of
Homeland Security.
ACTION: 30-Day notice and request for
comments; revision of an existing
collection of information.
AGENCY:
The Department of Homeland
Security, U.S. Customs and Border
Protection will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (PRA). The
information collection is published in
the Federal Register to obtain comments
from the public and affected agencies.
DATES: Comments are encouraged and
must be submitted (no later than April
13, 2022) to be assured of consideration.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT:
Requests for additional PRA information
should be directed to Seth Renkema,
Chief, Economic Impact Analysis
Branch, U.S. Customs and Border
Protection, Office of Trade, Regulations
and Rulings, 90 K Street NE, 10th Floor,
Washington, DC 20229–1177,
Telephone number 202–325–0056 or via
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:51 Mar 11, 2022
Jkt 256001
email CBP_PRA@cbp.dhs.gov. Please
note that the contact information
provided here is solely for questions
regarding this notice. Individuals
seeking information about other CBP
programs should contact the CBP
National Customer Service Center at
877–227–5511, (TTY) 1–800–877–8339,
or CBP website at https://www.cbp.gov/
.
SUPPLEMENTARY INFORMATION: CBP
invites the general public and other
Federal agencies to comment on the
proposed and/or continuing information
collections pursuant to the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501
et seq.). This proposed information
collection was previously published in
the Federal Register (Volume 86 FR
Page 63036) on November 15, 2021,
allowing for a 60-day comment period.
This notice allows for an additional 30
days for public comments. This process
is conducted in accordance with 5 CFR
1320.8. Written comments and
suggestions from the public and affected
agencies should address one or more of
the following four points: (1) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information will have
practical utility; (2) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
suggestions to enhance the quality,
utility, and clarity of the information to
be collected; and (4) suggestions to
minimize the burden of the collection of
information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology, e.g., permitting
electronic submission of responses. The
comments that are submitted will be
summarized and included in the request
for approval. All comments will become
a matter of public record.
Overview of This Information
Collection
Title: Vessel Entrance or Clearance
Statement.
OMB Number: 1651–0019.
Form Number: CBP Form 1300.
Current Actions: Revision of an
existing information collection.
Type of Review: Revision.
Affected Public: Businesses.
Abstract: CBP Form 1300, Vessel
Entrance or Clearance Statement, is
used to collect essential commercial
vessel data at time of formal entrance
and clearance in U.S. ports, allows the
master to attest to the truthfulness of all
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
CBP forms associated with the manifest
package, and collects relevant
information about the vessel and cargo.
The form was developed through
agreement by the United Nations
Intergovernmental Maritime
Organization (IMO) in conjunction with
the United States and various other
countries. The form was developed as a
single form to replace the numerous
other forms used by various countries
for the entrance and clearance of
vessels. CBP Form 1300 is authorized by
19 U.S.C. 1431, 1433, and 1434, and
provided for by 19 CFR 4.
This form is accessible at https://
www.cbp.gov/newsroom/publications/
forms?title=1300&=Apply.
This form is currently submitted in
paper format and is anticipated to be
submitted electronically as part of CBP’s
efforts to automate maritime forms
through the Vessel Entrance and
Clearance System (VECS), which will
reduce the need for paper submission of
any vessel entrance or clearance
requirements under the above
referenced statutes and regulations.
VECS will still collect and maintain the
same data as CBP Form 1300 but will
automate the capture of data to reduce
or eliminate redundancy with other data
collected by CBP.
Proposed Changes:
1. New ACE Account Type: CBP is
adding a new ACE Account type for
Vessel Agencies: The Vessel Agency
Portal Account. The new account type
within ACE will operate as a portal to
the Vessel Entrance and Clearance
System (VECS), which will run as its
own separate system.
Vessel Agents will be required to
provide identifying information such as;
their name, their employer
identification number (EIN), company
address, and their phone numbers,
which will be requested at the time
Vessel Agents apply for the new ACE
account type.
After creating an ACE account, Vessel
Agencies, Vessel Operating Common
Carriers (VOCCs), and their designees
maybe able to use the new Vessel
Entrance and Clearance System (VECS)
as part of a forthcoming pilot program
to test the functionality of VECS, and
will be able to file vessel entrance,
clearance, and related data to CBP
electronically.
2. VECS Public Pilot: VECS will
automate and digitize the collection and
processing of the data and filing
requirements for which the CBP Form
1300 is used. CBP plans to run an initial
public pilot to test the system. All users
who obtained a Vessel Agency Account
through the ACE Portal will be
automatically enrolled into the VECS
E:\FR\FM\14MRN1.SGM
14MRN1
]]>Agencies
[Federal Register Volume 87, Number 49 (Monday, March 14, 2022)]
[Notices]
[Pages 14277-14278]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-05286]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Innate Immune Memory Impacting HIV
Acquisition and/or Control (R21 Clinical Trial Not Allowed).
Date: April 11-12, 2022.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E71,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Lee G. Klinkenberg, Ph.D., Scientific Review
Officer, Scientific Review
[[Page 14278]]
Program, Division of Extramural Activities, National Institute of
Allergy and Infectious Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3E71, Rockville, MD 20852, 301-761-7749,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: March 8, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-05286 Filed 3-11-22; 8:45 am]
BILLING CODE 4140-01-P
